Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Exegenesis Bio Closes $10 Million Initial Funding from China Investors

publication date: Oct 21, 2019

Exegenesis Bio, a Philadelphia gene therapy company, raised over $10 million in initial funding from China investors, K2VC, Kaitai Capital and Lenovo Star. The company is developing affordable first-in-class and best-in-class gene therapies for high unmet needs, which it will market in China and globally. The company's executive team averages 15 years experience in cell and gene therapy in US companies. Zhenhua Wu, PhD, founder and CEO of Exegenesis, previously worked at several innovative biopharmas in the Philadelphia area and also at GSK and Merck. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here